MUNICH and MOSCOW, June 6 /PRNewswire/ -- Ingenium Pharmaceuticals AG, a drug discovery and development company, and ASINEX Ltd., a leading provider of lead generation and chemical optimization services, announced today a successful lead optimization project resulting in the generation of novel active compounds, which will expand Ingenium’s current proprietary pipeline of potential treatments for pain and inflammatory diseases. Due to the success of this completed project, the two companies will continue the collaboration throughout 2006.
Commenting on the agreement, Dr. Klaus Dembowsky, Ingenium’s Vice President of Drug Discovery, said, “As Ingenium continues to advance its drug discovery and development programs through preclinical pharmacological evaluation, effective lead optimization is critical. ASINEX has performed rapidly and efficiently to meet our needs and we have filed key patents based on these novel compounds.”
“We are looking forward to continuing our collaboration with Ingenium. After starting on a small scale, our relationship has grown over the last few months. We have successfully completed challenging tasks for Ingenium, and we are delighted that our work has made a positive impact on the company’s pipeline,” said Dr. Andrea Altieri, ASINEX’s Head of Project Management.
Ingenium Pharmaceuticals AG
Ingenium Pharmaceuticals discovers and develops novel therapeutics to treat pain and inflammatory diseases. The company applies its expertise and understanding of drug target biology, in vivo pharmacology and disease pathology to its growing portfolio of compounds and targets in these therapeutic areas. In addition, Ingenium has significant discovery and development collaborations with Elan and GPC Biotech as well as numerous agreements across the international biopharmaceutical industry to provide its unique genetics know-how and proprietary models. Based in Munich, Germany, Ingenium is financed by premier biotechnology-focused venture capital funds.
ASINEX
ASINEX (http://www.asinex.com) is a provider of ‘Intelligent Chemistry’ for lead generation and optimization. ASINEX is an innovative creator of novel high quality compound libraries for screening, and has more than 400,000 drug-like small molecules. With a total of 151 chemists (54 PhD), 9 computational chemists (7 PhD) and 38 biologists / biochemists (24 PhD), ASINEX is establishing itself as a company of choice for integrated drug discovery services.
Ingenium Pharmaceuticals AG
CONTACT: Michael Grau, CFO, +49 89 8565 2399, or Gretchen L. P.Schweitzer, +49 172 861 8540, both of Ingenium Pharmaceuticals AG; orAndrea Altieri, Head of Project Management of ASINEX, +7 095 728 3891,busdev@asinex.com
